Gynecological Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_17_3488 - Variation in Hematologic Toxicity in Patients Undergoing Radiation Therapy With Concurrent Weekly Cisplatin for Head and Neck Versus Cervical Cancer

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Variation in Hematologic Toxicity in Patients Undergoing Radiation Therapy With Concurrent Weekly Cisplatin for Head and Neck Versus Cervical Cancer
E. Sojourner1, H. Park1, C. H. Feng1, L. Vitzthum1, I. Sirak2, L. Wei3, R. R. Tarnawski4, U. M. Mahantshetty5, and L. K. Mell1; 1University of California, San Diego, La Jolla, CA, 2Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic, 3Xijing Hospital, Xian 710032, China, 4Maria Sklodowska-Curie Cancer Center and Institute of Oncology Gliwice Branch, Gliwice, Poland, 5Tata Memorial Hospital, Mumbai, India

Purpose/Objective(s): Hematologic toxicity is a common dose-limiting complication of concurrent chemoradiotherapy. Toxicity varies as a function of dose and the volume of active bone marrow (ABM) irradiated, but the extent to which regional variation in active marrow impacts toxicity is not well understood. We examined differences in hematologic toxicity between patients receiving radiation to higher volume (i.e. pelvic) vs lower volume (i.e. head and neck) of ABM with identical concurrent chemotherapy. We hypothesized that patients who had higher volume vs lower volume of ABM irradiated during concurrent chemotherapy would have a corresponding increase in hematologic toxicity.

Materials/Methods: We reviewed 126 patients (90 cervical cancer, 36 head and neck cancer (HNC)) treated with concurrent chemoradiation using weekly cisplatin (40 mg/m2) between April 2011 and January 2018. Patients were included if they received at least 5 cycles of weekly cisplatin with definitive or postoperative intensity modulated radiation therapy. Patients were excluded if they had previous radiation at the site within the last five years or had other systemic therapy prior to chemoradiotherapy. Weekly complete blood counts were collected for all patients. We compared log-transformed blood counts at baseline and nadirs in both disease cohorts and in female vs male HNC patients using a two sample t-test.

Results: Baseline white blood cell (WBC) (p=0.36), absolute neutrophil (ANC) (p=0.39), hemoglobin (p=0.34), and hematocrit (p=0.34) counts were not significantly different between cervical and HNC patients. WBC nadirs and ANC nadirs were significantly lower in cervical cancer patients compared to HNC patients (p=.003 and p=.001, respectively). Baseline and nadir WBC (p=0.28, p=.32), ANC (p=0.27, p=0.33), hemoglobin (p=0.87, p=0.69), and hematocrit counts (p=0.99, p=0.93) were not significantly different between male and female HNC patients.

Conclusion: Patients treated for cervical cancer had increased hematologic toxicity, specifically leukocytopenia and neutropenia, compared to patients treated for HNC receiving the same chemotherapy regimen. Male and female HNC patients do not appear to have a significant difference in development of hematologic toxicity. Future work will compare ABM and compensatory response in irradiated and non-irradiated regions.

Author Disclosure: E. Sojourner: None. H. Park: None. C.H. Feng: None. L. Vitzthum: None. I. Sirak: None. L. Wei: None. R.R. Tarnawski: None. U.M. Mahantshetty: None.

Send Email for Elena Sojourner


Assets

TU_17_3488 - Variation in Hematologic Toxicity in Patients Undergoing Radiation Therapy With Concurrent Weekly Cisplatin for Head and Neck Versus Cervical Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Variation in Hematologic Toxicity in Patients Undergoing Radiation Therapy With Concurrent Weekly Cisplatin for Head and Neck Versus Cervical Cancer